TY - JOUR
T1 - Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia
T2 - Results from the Prostate Cancer Prevention Trial
AU - Kristal, Alan R.
AU - Schenk, Jeannette M.
AU - Song, Yoon Ju
AU - Arnold, Kathryn B.
AU - Neuhouser, Marian L.
AU - Goodman, Phyllis J.
AU - Lin, Daniel W.
AU - Stanczyk, Frank Z.
AU - Thompson, Ian M.
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2008/12
Y1 - 2008/12
N2 - The authors conducted a nested case-control study of serum steroid concentrations and risk of benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH over 7 years (n = 708) was defined as receipt of treatment, a report of 2 International Prostate Symptom Score (IPSS) values greater than 14, or 2 increases of 5 or more from baseline IPSS values with at least 1 value greater than or equal to 12. Controls (n = 709) were selected from men who reported no BPH treatment or any IPSS greater than 7. Baseline serum was analyzed for testosterone, estradiol, estrone, 5α-androstane-3α, 17β-diol-glucuronide, and sex hormone-binding globulin. Covariate-adjusted odds ratios contrasting the highest quartiles with the lowest quartiles of testosterone, estradiol, and testosterone:17β-diol-glucuronide ratio were 0.64 (95% confidence interval (CI): 0.43, 0.95; Ptrend = 0.04), 0.72 (95% CI: 0.53, 0.98; Ptrend = 0.09), and 0.64 (95% CI: 0.46, 0.89; Ptrend = 0.004), respectively. Findings did not differ by age, body mass index, time to BPH endpoint, or type of BPH endpoint. High testosterone levels, estradiol levels, and testosterone:17β-diol-glucuronide ratio are associated with reduced BPH risk, which may reflect decreased activity of 5-α-reductase. Genetic or environmental factors that affect the activity of 5-α-reductase may be important in the development of symptomatic BPH.
AB - The authors conducted a nested case-control study of serum steroid concentrations and risk of benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH over 7 years (n = 708) was defined as receipt of treatment, a report of 2 International Prostate Symptom Score (IPSS) values greater than 14, or 2 increases of 5 or more from baseline IPSS values with at least 1 value greater than or equal to 12. Controls (n = 709) were selected from men who reported no BPH treatment or any IPSS greater than 7. Baseline serum was analyzed for testosterone, estradiol, estrone, 5α-androstane-3α, 17β-diol-glucuronide, and sex hormone-binding globulin. Covariate-adjusted odds ratios contrasting the highest quartiles with the lowest quartiles of testosterone, estradiol, and testosterone:17β-diol-glucuronide ratio were 0.64 (95% confidence interval (CI): 0.43, 0.95; Ptrend = 0.04), 0.72 (95% CI: 0.53, 0.98; Ptrend = 0.09), and 0.64 (95% CI: 0.46, 0.89; Ptrend = 0.004), respectively. Findings did not differ by age, body mass index, time to BPH endpoint, or type of BPH endpoint. High testosterone levels, estradiol levels, and testosterone:17β-diol-glucuronide ratio are associated with reduced BPH risk, which may reflect decreased activity of 5-α-reductase. Genetic or environmental factors that affect the activity of 5-α-reductase may be important in the development of symptomatic BPH.
KW - Gonadal steroid hormones
KW - Prostatic hyperplasia
UR - http://www.scopus.com/inward/record.url?scp=57749180591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57749180591&partnerID=8YFLogxK
U2 - 10.1093/aje/kwn272
DO - 10.1093/aje/kwn272
M3 - Article
C2 - 18945688
AN - SCOPUS:57749180591
VL - 168
SP - 1416
EP - 1424
JO - American Journal of Epidemiology
JF - American Journal of Epidemiology
SN - 0002-9262
IS - 12
ER -